Neuraxis (NRXS) Other Non Operating Income (2022 - 2025)
Neuraxis (NRXS) posted Other Non Operating Income of -$67390.0 for Q4 2025, down 196.73% sequentially from -$22711.0 in Q3 2025, and down 595.95% YoY from $13588.0 in Q4 2024.
Neuraxis (NRXS) Other Non Operating Income (2022 - 2025) Analysis & Trends
Neuraxis has reported Other Non Operating Income for 4 years, with the latest figure at -$67390.0 in Q4 2025.
- Quarterly Other Non Operating Income fell 595.95% year-over-year to -$67390.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$46247.0 (up 87.7% YoY) and the FY2025 annual result came in at $29353.0, down 12.69% from the prior year.
- Other Non Operating Income slipped to -$67390.0 in Q4 2025 per NRXS's latest filing, from -$22711.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.4 million in Q4 2022 and troughed at -$3.7 million in Q4 2023.
- A 4-year average of -$226425.9 and a median of -$22711.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income plunged 1725.91% in 2024, then surged 826.71% in 2025.
- Over 4 years, Other Non Operating Income stood at $2.4 million in 2022, then slumped by 253.03% to -$3.7 million in 2023, then soared by 100.37% to $13588.0 in 2024, then slumped by 595.95% to -$67390.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$67390.0, -$22711.0, and $27440.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -67,390.00 |
| Sep 30, 2025 | -22,711.00 |
| Jun 30, 2025 | 27,440.00 |
| Mar 31, 2025 | 16,414.00 |
| Dec 31, 2024 | 13,588.00 |
| Sep 30, 2024 | -103,961.00 |
| Jun 30, 2024 | 2,961.00 |
| Mar 31, 2024 | -288,531.00 |
| Dec 31, 2023 | -3.66 Mn |
| Sep 30, 2023 | 6,394.00 |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | -876,558.00 |
| Jun 30, 2022 | -846,948.00 |